Genetic screening for mutated transthyretin is warranted in elderly patients with increased left ventricular wall thickness, as 5% of patients diagnosed with hypertrophic cardiomyopathy actually have mTTR-FAC.
Five per cent of patients diagnosed with hypertrophic cardiomyopathy have mTTR-FAC. Mutated transthyretin genetic screening is warranted in elderly subjects with increased LVWT, particularly, those of African descent with neuropathy, carpal tunnel syndrome, ECG low voltage, or LGE.
Damy et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: